Actinium Pharmaceuticals Inc (ATNM)

$1.11 +0.02 (1.83%)
Market Cap 34.32M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 177,500
Avg Vol 115,942
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 29%
Beta -0.31
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
dm4
dm4 Mar. 21 at 2:00 AM
$ATNM https://x.com/us_fda/status/2034984274290520199?s=12&t=OgLhSpWTIRlbsCZBSb2a-w
0 · Reply
dm4
dm4 Mar. 21 at 1:50 AM
$ATNM Commissioner's National Priority Voucher (CNPV) Pilot Program | FDA https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program
0 · Reply
dm4
dm4 Mar. 21 at 1:27 AM
$ATNM More from Dr. Makary. All he emphasizes resonates strongly with IOMAB! Has ATNM resubmitted to this new FDA? https://x.com/drmakaryfda/status/2035124202886267148?s=12&t=OgLhSpWTIRlbsCZBSb2a-w
1 · Reply
Biotrad3r
Biotrad3r Mar. 20 at 11:41 PM
$ATNM @Pinto72 You’re not too smart are you kid? End of the Year tax loss selling only happens end of the year 😂 Probably dont worry about tax laws living in your mom’s basement eh?
0 · Reply
Pinto72
Pinto72 Mar. 20 at 7:44 PM
$ATNM Did I read that correctly? Are people still tax loss selling in the new year? It’s only DOOOOOOOOWN 25% since your post! 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
Xarevira
Xarevira Mar. 20 at 7:06 PM
$ATNM 10K today or next Friday?
0 · Reply
gooddoggie
gooddoggie Mar. 20 at 6:56 PM
$ATNM There is no reason to worry. At any moment our existence can blink out in a maelstrom of fire. I've seen a lot of doom and gloom and depressing things, and it is natural to feel that all is lost - because it is. The best that we can do is to be kindly and helpful toward our friends and fellow passengers who are clinging to the same speck of dirt while we are drifting side by side to our common doom. Have a great weekend!
0 · Reply
mauryrosen
mauryrosen Mar. 20 at 6:03 PM
$ATNM https://www.bloomberg.com/news/articles/2026-03-20/novartis-to-acquire-breast-cancer-drug-in-up-to-3-billion-deal?embedded-checkout=true Maybe Seth should think about getting a new bridesmaid dress ….. the one he has must be so beaten up and frayed by now. Bullish with Psychosis
1 · Reply
Jimmy1940
Jimmy1940 Mar. 20 at 4:32 PM
$ATNM -$0.63 Down (36.84%) Past 3 Months Not Good Damn-it
0 · Reply
Pinto72
Pinto72 Mar. 20 at 4:21 AM
$ATNM BANKRUPTCY AS SOON!!!!🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!!🤣🤣🤣🤣🤣🤣
0 · Reply
Latest News on ATNM
BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

Feb 17, 2026, 8:00 AM EST - 4 weeks ago

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Dec 12, 2025, 8:45 AM EST - 3 months ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Dec 1, 2025, 8:45 AM EST - 3 months ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Nov 17, 2025, 8:30 AM EST - 4 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2025, 8:30 AM EDT - 5 months ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:10 PM EDT - 5 months ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 13, 2025, 8:30 AM EDT - 5 months ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 8 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 9 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 10 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 11 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 11 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 11 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 11 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 11 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 11 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 11 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 11 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 1 year ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

dm4
dm4 Mar. 21 at 2:00 AM
$ATNM https://x.com/us_fda/status/2034984274290520199?s=12&t=OgLhSpWTIRlbsCZBSb2a-w
0 · Reply
dm4
dm4 Mar. 21 at 1:50 AM
$ATNM Commissioner's National Priority Voucher (CNPV) Pilot Program | FDA https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program
0 · Reply
dm4
dm4 Mar. 21 at 1:27 AM
$ATNM More from Dr. Makary. All he emphasizes resonates strongly with IOMAB! Has ATNM resubmitted to this new FDA? https://x.com/drmakaryfda/status/2035124202886267148?s=12&t=OgLhSpWTIRlbsCZBSb2a-w
1 · Reply
Biotrad3r
Biotrad3r Mar. 20 at 11:41 PM
$ATNM @Pinto72 You’re not too smart are you kid? End of the Year tax loss selling only happens end of the year 😂 Probably dont worry about tax laws living in your mom’s basement eh?
0 · Reply
Pinto72
Pinto72 Mar. 20 at 7:44 PM
$ATNM Did I read that correctly? Are people still tax loss selling in the new year? It’s only DOOOOOOOOWN 25% since your post! 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
Xarevira
Xarevira Mar. 20 at 7:06 PM
$ATNM 10K today or next Friday?
0 · Reply
gooddoggie
gooddoggie Mar. 20 at 6:56 PM
$ATNM There is no reason to worry. At any moment our existence can blink out in a maelstrom of fire. I've seen a lot of doom and gloom and depressing things, and it is natural to feel that all is lost - because it is. The best that we can do is to be kindly and helpful toward our friends and fellow passengers who are clinging to the same speck of dirt while we are drifting side by side to our common doom. Have a great weekend!
0 · Reply
mauryrosen
mauryrosen Mar. 20 at 6:03 PM
$ATNM https://www.bloomberg.com/news/articles/2026-03-20/novartis-to-acquire-breast-cancer-drug-in-up-to-3-billion-deal?embedded-checkout=true Maybe Seth should think about getting a new bridesmaid dress ….. the one he has must be so beaten up and frayed by now. Bullish with Psychosis
1 · Reply
Jimmy1940
Jimmy1940 Mar. 20 at 4:32 PM
$ATNM -$0.63 Down (36.84%) Past 3 Months Not Good Damn-it
0 · Reply
Pinto72
Pinto72 Mar. 20 at 4:21 AM
$ATNM BANKRUPTCY AS SOON!!!!🚀🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!!🤣🤣🤣🤣🤣🤣
0 · Reply
johnny4cures
johnny4cures Mar. 20 at 3:29 AM
$ATNM "We look forward to sharing additional details once the abstracts are publicly released in accordance with AACR guidelines."" Yes indeed
1 · Reply
RadioIsotope25
RadioIsotope25 Mar. 19 at 8:46 PM
$RADX $AKTS $CATX $ATNM
0 · Reply
tjm1
tjm1 Mar. 19 at 7:55 PM
$ATNM ATNM over the last year
0 · Reply
tjm1
tjm1 Mar. 19 at 7:54 PM
$ATNM Relmada Therapeutics over the last year
0 · Reply
johnny4cures
johnny4cures Mar. 19 at 9:01 AM
$ATNM Gates-backed TerraPower sketches out $450M radioisotope facility https://share.google/pY701LCHMyTn7T0c7
2 · Reply
dm4
dm4 Mar. 18 at 11:29 PM
$ATNM “deliver for the American people”, “more cures and meaningful treatment for the American public” IOMAB belongs to this category - needs to be delivered! https://x.com/drmakaryfda/status/2034389213668335678?s=12&t=OgLhSpWTIRlbsCZBSb2a-w
1 · Reply
Pinto72
Pinto72 Mar. 18 at 7:46 PM
$ATNM AAVIE!!!!!!! BANKRUPTCY AS SOON!!!!🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣
0 · Reply
Pickerbefore
Pickerbefore Mar. 18 at 4:07 PM
$ATNM 10-k due soon. Steve O had the sense to leave before it is issued and spared the disgusting picture painted by the artist Sandesh Seth. Disgusting.
1 · Reply
fibonacci1170
fibonacci1170 Mar. 18 at 9:45 AM
$ATNM wow this thing still exists? Any idea why: 1. Atnm did not approach the OND to appeal against the FDA, like akba and ardx successfully did. 2. Atnm never filed with MHRA and EMA. 3. No lawsuits against the FDA by patients and doctors. There is no way a drug that enabled 100% BMT access does not get approved.
3 · Reply
Pinto72
Pinto72 Mar. 18 at 4:55 AM
$ATNM DONNA!!!!!!!! BANKRUPTCY = AS SOON!!!!!! eXtReEmLeE bUlLiSh!!!!!🤣🤣🤣🤣🤣🤣
0 · Reply
gooddoggie
gooddoggie Mar. 18 at 1:00 AM
$ATNM Waiting for something to drop. And not abstract. Need something more solid.
2 · Reply
gooddoggie
gooddoggie Mar. 17 at 11:51 PM
$ATNM I’ll give Seth one thing - he got this far without saddling ATNM with massive debt. Sure, he killed us with offerings, a RS, and ATMs, but at least we he didn’t do all that PLUS take on a bunch of creditors standing first place in line to be paid.
0 · Reply